Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Download All

Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer, including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides, commentaries, podcast, on-demand Webcast, and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors.

Donna M. Fitzgerald, PA-C, MPAS
Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Marissa Marti, APRN, AGNP-C, AOCNP
Joyce O'Shaughnessy, MD
Laura M. Spring, MD

On-Demand Webcast

Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 8, 2021 Expired: April 7, 2022

Downloadable Slidesets with ExpressPoints

Gain key clinical insights fast, with this short slideset from CCO on the optimal use of CDK4/6 and PIK3CA inhibitors for patients with HR+/HER2 breast cancer.  

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 9, 2021

Download these slides from a live Webinar to gain expert insight on the new and emerging data on the optimal use of CDK4/6 and PI3K inhibitors for patients with HR+/HER2 breast cancer.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 5, 2021

Audio Podcast

In an engaging discussion led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Dr. Sara Hurvitz, MD, FACP, share how they currently use CDK4/6 inhibitors for their patients with metastatic HR-positive/HER2-negative breast cancer, the potential clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021, and strategies for counseling patients receiving CDK4/6 inhibitors.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: August 19, 2021

Downloadable slides accompanying a podcast led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, about how they use CDK4/6 inhibitors for patients with HR-positive/HER2-negative breast cancer, including key studies on CDK4/6 inhibitors from ASCO 2021.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: August 24, 2021

ClinicalThought

Faculty review recent clinical trial data and provide their insights on the use of CDK4/6 inhibitors and PI3K inhibitors for HR+/HER2- breast cancer.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 23, 2021

Hear expert perspective from Laura M. Spring, MD, on how she will integrate adjuvant abemaciclib into clinical practice.

Laura M. Spring, MD Released: November 29, 2021

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with oral targeted therapy for HR-positive, HER2-negative breast cancer from 5 experts.

Donna M. Fitzgerald, PA-C, MPAS Matthew P. Goetz, MD Marissa Marti, APRN, AGNP-C, AOCNP Joyce O'Shaughnessy, MD Laura M. Spring, MD Released: September 14, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue